Skip to main content
. Author manuscript; available in PMC: 2018 May 30.
Published in final edited form as: Circulation. 2017 Aug 9;136(14):1304–1314. doi: 10.1161/CIRCULATIONAHA.117.028885

Table 1.

Baseline Clinical and Angiographic Characteristics

Ridaforolimus-Eluting Stent (N=958, 1276 Lesions) Zotarolimus-Eluting Stent (N=961, 1277 Lesions)
Age, y 63.7±10.2 63.1±10.3
Male sex 78.3 (750/958) 81.9 (787/961)
Diabetes mellitus 32.8 (314/958) 32.3 (310/961)
Hypertension 72.4 (687/949) 74.0 (704/951)
Hyperlipidemia 80.4 (759/944) 78.1 (744/953)
Previous myocardial infarction 31.1 (298/958) 30.5 (293/961)
Previous PCI 38.8 (372/958) 38.2 (367/961)
Previous coronary bypass surgery 8.8 (84/958) 9.6 (92/961)
Current smoker 23.4 (224/958) 19.4 (186/961)
LV ejection fraction 55.5±9.8 55.8±9.3
Clinical presentation
 Stable coronary disease 59.3 (568/958) 61.3 (589/961)
 ACS 40.7 (390/958) 38.7 (372/961)
 Elevated cardiac biomarkers* 27.0 (206/763) 28.2 (216/766)
Target lesion vessel
 Left main 1.1 (14/1276) 0.4 (5/1277)
 Left anterior descending 40.7 (519/1276) 39.7 (507/1277)
 Right coronary 32.0 (408/1276) 32.2 (411/1277)
 Left circumflex 24.4 (311/1276) 25.1 (320/1277)
 Bypass graft 1.9 (24/1276) 2.7 (34/1277)
 Multivessel disease 29.4 (282/958) 29.3 (282/961)
Angiographic complexity
 No. lesions treated per patient 1.3±0.6 1.3±0.6
 Reference vessel diameter (mm) 2.73±0.49 2.74±0.49
 Lesion length (mm) 17.7±10.8 17.9±10.7
 SYNTAX score 11.2±7.4 11.0±7.2
 TIMI 0 flow in target vessel 9.7 (92/953) 7.7 (74/957)
 Bifurcation lesion 28.6 (365/1276) 29.1 (371/1277)
 Ostial lesion 6.0 (77/1276) 6.1 (78/1277)
 Chronic total occlusion 7.2 (92/1272) 5.8 (74/1276)
 Overlapping stents 24.7 (237/958) 23.1 (222/961)
 Use of atherectomy device 0.9 (9/958) 1.1 (11/961)
 Thrombus present 3.4 (43/1270) 3.0 (38/1275)
 Severe calcification 13.3 (169/1272) 10.5 (134/1274)
 Severe tortuosity 3.9 (50/1271) 2.8 (35/1272)
 ACC lesion class B2/C 57.5 (733/1275) 58.9 (752/1277)

ACC indicates American College of Cardiology; ACS, acute coronary syndrome; LV, left ventricle; PCI, percutaneous coronary intervention; SYNTAX, synergy between percutaneous coronary intervention with taxus and cardiac surgery; and TIMI, thrombolysis in myocardial infarction. Values are % (n/N) or mean±SD.

*

Troponin I or T ≥3X upper limit of normal.